Results 121 to 130 of about 35,587 (246)
Supplementary Data #2 from Genomic Profiling Identifies Association of <i>IDH1/IDH2</i> Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
, 2023 Guo Zhu, Khédoudja Nafa, Narasimhan P. Agaram, Ahmet Zehir, Ryma Benayed, Justyna Sadowska, Laetitia Borsu, Ciara M. Kelly, William D. Tap, Nicola Fabbri, Edward A. Athanasian, Patrick J. Boland, John H. Healey, Michael F. Berger, Marc Ladanyi, Meera Hameed +15 moreopenalex +1 more sourceChemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial
Cancer, Volume 131, Issue 23, 1 December 2025.Abstract Background
Given the poor prognosis of IDH wild‐type (IDH‐wt) and telomerase reverse transcriptase promoter mutation (TERTp‐mut) histological grade 2 to 3 gliomas, the World Health Organization has reclassified it as molecular glioblastoma. However, the effectiveness of chemoradiotherapy (CRT) in these patients remains unclear, especially in ...Jing Zhang, Peng Wang, Yin Ren, Li Chen, Jin Feng, Fei Liu, Kaiwen Deng, Zhaoshi Bao, Xiaoguang Qiu, Yanwei Liu +9 morewiley +1 more sourceUnraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomas [PDF]
Xiang Li, Yiran Tao, Yuan Lyu, Junqi Li, Wulong Liang, Wanqing Liu, Nan Hu, Jing Zhou, Zian Li, 篠原 正徳, Lirui Dai, Yuqian Zheng, Zimin Shi, Weihua Hu, Shaolong Zhou, Qiao Shan, Xudong Fu, Xinjun Wang +17 moreopenalex +1 more sourceSupplementary Figure S3 from Radioprotection of <i>IDH1</i>-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
, 2023 Remco J. Molenaar, Dennis Botman, Myrthe A. Smits, Vashendriya V. Hira, Sanne A. van Lith, Jan Stap, Peter Henneman, Mohammed Khurshed, Krissie Lenting, Adri N. Mul, Dionysia Dimitrakopoulou, Cornelis M. van Drunen, Ron A. Hoebe, Tomas Radivoyevitch, Johanna W. Wilmink, Jaroslaw P. Maciejewski, W. Peter Vandertop, William P. J. Leenders, Fonnet E. Bleeker, Cornelis J.F. Van Noorden +19 moreopenalex +1 more sourceMechanisms, impacts and therapeutic strategies of glucose metabolic reprogramming in tumours
Clinical and Translational Discovery, Volume 5, Issue 6, December 2025.Tumour metabolic reprogramming initiates a vicious cycle of immunosuppression and therapy resistance. This synergy disarms immunity and fortifies tumour cells, ultimately driving clonal evolution of resistant disease. Abstract Background
Glucose metabolic reprogramming is a hallmark of cancer, best exemplified by the Warburg effect.Li Ma, Ming‐yang Wu, Cui‐cui Tian, Hao‐ze Shi, Dan Song +4 morewiley +1 more sourceData from Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation
, 2023 Zhuo Yang, Nan Hu, Weiwei Wang, Weihua Hu, Shaolong Zhou, Jianxiang Shi, Minghe Li, Jing Zhou, Chao Chen, Xuyang Zhang, Ruyi Yang, Xudong Fu, Xinjun Wang +12 moreopenalex +1 more sourceIntegrated pathway analysis identifies prognostically relevant subtypes of glioblastoma characterized by abnormalities in multi‐omics
Clinical and Translational Medicine, Volume 15, Issue 12, December 2025.We report the interaction between tumour cells and environmental immune cells, classifying GBM into two main subtypes: (1) The tumour‐driving subtype is characterized by multiple oncogenic mutations, while (2) the immune‐blockage subtype is marked by a high presence of immune cells.Pei Zhang, Dan Liu, Tonghui Yu, Yanlin Zhang, Lu Zhong, Xiao Ouyang, Qin Xia, Lei Dong +7 morewiley +1 more sourceBlast Clearance Dynamics and Time to Response Across IDH1‐ and IDH2‐Mutated AML
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Background
IDH mutations are found in 15%–20% of acute myeloid leukemia (AML). Recent evidence suggests that IDH mutation subtypes may respond differently to intensive chemotherapy. We evaluated blast clearance patterns, remission outcomes, and overall survival (OS) in AML patients with IDH2 R140, IDH2 R172, and IDH1 R132 mutations to assess ...Mohamad Sheikh Najeeb, Oudai Alkabbani, Rong He, Dragan Jevremovic, Patricia T. Greipp, Aasiya Matin, Mehrdad Hefazi, Abishek Mangaonkar, Mrinal Patnaik, Naseema Gangat, William J. Hogan, Mark R. Litzow, Cecila Y. Arana Yi, James M. Foran, Hassan B Alkhateeb, Mithun Shah, Kebede Begna, Tariq Kewan, Antoine N. Saliba, Aref Al‐Kali +19 morewiley +1 more source
